---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-016883"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2026-05-14T12:05:14+00:00"
generated_at: "2026-05-14T12:25:51.244751+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Genprex diabetes gene therapy GPX-002 reverses hyperglycemia in T2D mouse model

## Summary
- Preclinical data presented at ASGCT 2026 showed GPX-002 reversed hyperglycemia in Type 2 diabetic mice within 4 weeks.
- Treatment improved β-cell function: increased insulin granules, improved glucose-stimulated insulin secretion vs controls.
- β-cell-specific targeting (RIP-PM-GFP) also reversed hyperglycemia, indicating enhanced β-cell maturation.
- Approach is translatable to humans via endoscopic retrograde cholangiopancreatography delivery to the pancreas.

## SEC filing metadata
- accession: 0001437749-26-016883
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2026-05-14T12:05:14+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774926016883/0001437749-26-016883-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774926016883/gnpx20260513_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-016883
- JSON: https://secwatch.observer/filing/0001437749-26-016883.json
- Plain text: https://secwatch.observer/filing/0001437749-26-016883.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.